Value proposition

A preclinical stage biotech company developing novel therapies to treat cancer by targeting cells from the immune system

Founded in 2017 and headquartered in Paris, France, Alderaan Biotechnology works with world-class teams in the fields of immunomodulation and immunotherapy of cancer focusing on the development of monoclonal antibodies with technologies aiming at Treg depletion in solid tumours.

The company raised €1.5M ($1.7M) in 2017 from co-founder AdBio partners and €18.5M ($20.7M) in 2019 from AdBio partners and Medicxi.

Alderaan Biotechnology works in partnership with the French national Institute for health and medical research (INSERM) and with the Institut Paoli Calmettes, Marseille, France.